
| 2020 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Project Funding per Partner: | > 1000 |
| Total Number of Projects: | > 1000 |
| 2019 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Project Funding per Partner: | > 1000 |
| Total Number of Projects: | > 1000 |
Total number of projects: 3
As coordinator: 0
As participant: 3
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2021 | 0 | 8.728.185 | 476.000 | 1 | ||
| 2020 | 0 | 11.381.970 | 505.000 | 1 | ||
| 2019 | 0 | 10.999.316 | 288.750 | 1 | ||
Total number of partners: 73
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 73
Frequent / Rare Partner Ratio: 0
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2021-01-01 | Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy | T2EVOLVE | participant | 8.728.185 | 29 |
| 2020-10-01 | The RapiD and SecuRe AI enhAnced DiaGnosis, Precision Medicine and Patient EmpOwerment Centered Decision Support System for Coronavirus PaNdemics | DRAGON | participant | 11.381.970 | 19 |
| 2019-12-01 | Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies | imSAVAR | participant | 10.999.316 | 28 |